Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease

CT-P13 is equivalent to reference product in primary outcome; no difference in safety outcomes

Source link

Related posts

YAP1-induced MALAT1 promotes epithelial–mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer


Geriatric IBD mortality trend highlights need for ‘more standardized guidelines’


Doppler Probe Use Is Cost Effective in Nonvariceal Upper GI Bleeding


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy